Last reviewed · How we verify
Methylaminolevulinate PDT in 2 sessions
At a glance
| Generic name | Methylaminolevulinate PDT in 2 sessions |
|---|---|
| Also known as | Metvix 160 mg/g creme, CAS number 33320-16-0, ATC code L01XD03, RVG 31130 |
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Daylight-PDT With MAL for AK and Photodamaged Skin (PHASE4)
- Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: